22960-16-3

Basic information

• Product Name: Isoquinoline-4-carbaldehyde
• Synonyms: RARECHEM AK ML 0134;ISOQUINOLINE-4-CARBALDEHYDE;4-ISOQUINOLINECARBOXALDEHYDE;4-Isoquinolinecarboxaldehyde (7CI,8CI,9CI);4-Formylisoquinoline;Isoquinoline-4-carboxaldehyde;Isoquinoline-4-carbaldehyde ,98%;4-Isoquinolinecarboxaldehyde 97%
• CAS NO: 22960-16-3
• Molecular Formula: C₁₀H₇NO
• Molecular Weight: 157.17
• Product Categories: ALDEHYDE;Carbonyl Compounds;Heterocycles;Isoquinoline Derivertives;Building Blocks;Isoquinoline
• Mol File: 22960-16-3.mol

Chemical Properties

• Melting Point: 101-106℃
• Boiling Point: 331.718 °C at 760 mmHg
• Flash Point: 162.428 °C
• Appearance: /
• Density: 1.224 g/cm³
• Vapor Pressure: 0.000153mmHg at 25°C
• Refractive Index: 1.687
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.49±0.10(Predicted)
• CAS DataBase Reference: Isoquinoline-4-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: Isoquinoline-4-carbaldehyde(22960-16-3)
• EPA Substance Registry System: Isoquinoline-4-carbaldehyde(22960-16-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36-36/37/38-20/21/22
• Safety Statements: 26-36/37/39-22
• RIDADR: 2811
• WGK Germany: 3
• Hazardous Substances Data: 22960-16-3(Hazardous Substances Data)

Usage

Chemical Properties

Off-white to yellow or brown solid

InChI:InChI=1/C10H7NO/c12-7-9-6-11-5-8-3-1-2-4-10(8)9/h1-7H

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 1532-97-4 4-bromoisoquinoline 
• 50978-45-5 3-oxobenzo[d]isothiazole-2(3H)-carbaldehyde 1,1-dioxide 
• 109-72-8 n-butyllithium 
• 330435-61-5 2,2-dimethyl-5-(2-formylphenyl)-4H-1,3-dioxin 
• 32117-82-1 N-methoxy-N-methyl-formamide 

Downstream Products

• 20335-71-1 3-benzoylisoquinoline 
• 73048-60-9 4-(hydroxymethyl)isoquinoline 
• 372077-34-4 4-isochinolinyl-(5-methoxy-1-phenylsulfonyl-1H-2-indolyl)-methanone 
• 111164-76-2 2--acetonitril 
• 370580-21-5 4-isochinolinyl-(5-methoxy-1-phenylsulfonyl-1H-2-indolyl)-methanol 
• 112518-81-7 4-Formyl-1-prop-2-ynyl-1H-isoquinoline-2-carboxylic acid methyl ester 

Relevant articles and documents

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.

Palladium-catalyzed reductive carbonylation of aryl halides with N-formylsaccharin as a CO source

Easy peasy: The title reaction employs N-formylsaccharin, which is an easily accessible crystalline compound, as an effective CO source. The reactions proceed with a small excess of the CO source at moderate temperatures and were successfully applied to a wide range of aryl bromides. DMF=N,N- dimethylformamide, dppb=1,4-bis-(diphenylphosphino)butane. Copyright

TRPA1 ANTAGONISTS

Compounds of formula (I), wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Highly selective recognition of a-chiral primary organoammonium ions by C3-symmetric peptide receptors

A straightforward synthesis of C3-symmet:ric, imidazole-containing, macrocyclic peptides with different binding arms is presented, The chirality of the backbone and the selection of adequate receptor arms make these systems highly selective receptors for α-chiral primary organoammonium ions. Furthermore, the receptors have the ability to discriminate between enantiomeric guests with selectivity ratios of up to 87:13, The binding constants and the selectivity ratios were estimated by standard 1H NMR titration techniques in CDCl3.

4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS

The present invention provides compounds of formula (I) where n, R1, R2, R3, R4, R5 and Heteroaryl are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such,

Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.